Additionally, a phase IIa trial investigating the efficacy of the HER2-targeted monoclonal antibody pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer or cancer of the gastro-oesophageal junction was the basis for an ongoing phase III study of first-line pertuzumab, trastuzumab and chemotherapy in HER2-positive metastatic gastric and gastro-oesophageal junction cancer (JACOB, NCT01774786) (Kang et al. 2014). Here, ERBB2 is linked to cancer.